Johnson & Johnson (NYSE:JNJ) Shares Sold by GSB Wealth Management LLC

GSB Wealth Management LLC cut its position in Johnson & Johnson (NYSE:JNJGet Rating) by 0.7% in the first quarter, HoldingsChannel reports. The institutional investor owned 46,111 shares of the company’s stock after selling 306 shares during the period. Johnson & Johnson makes up 2.4% of GSB Wealth Management LLC’s portfolio, making the stock its 2nd biggest holding. GSB Wealth Management LLC’s holdings in Johnson & Johnson were worth $8,172,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of JNJ. Family CFO Inc acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $26,000. Steward Financial Group LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $34,000. Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson during the 1st quarter worth $38,000. Advocacy Wealth Management Services LLC grew its stake in Johnson & Johnson by 41.4% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after purchasing an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $49,000. 68.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several analyst reports. Wells Fargo & Company boosted their target price on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Raymond James upped their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. UBS Group lowered their price objective on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Morgan Stanley upped their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, July 8th. Finally, Daiwa Capital Markets began coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating for the company. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 0.3 %

Johnson & Johnson stock opened at $173.20 on Thursday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company has a market capitalization of $455.76 billion, a P/E ratio of 25.21, a PEG ratio of 3.28 and a beta of 0.63. The stock has a 50-day simple moving average of $175.99 and a 200-day simple moving average of $174.36.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.48 EPS. Equities research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.61%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.